MemoText
MEMOTEXT Corporation is a Toronto-based digital health platform company that co-creates and commercializes personalized, omnichannel patient-engagement programs and digital therapeutics — most notably the A4i schizophrenia DTx via a CAMH joint venture — for enterprise health systems, pharma, payers, and academic medical centers across North America.
- Company typePrivate
- Founded2012
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What MemoText does
MEMOTEXT Corporation is a Toronto-based digital health company founded by Amos Adler that operates a data-driven, evidence-based platform for personalized patient engagement and digital therapeutics. The platform enables co-creation of omnichannel digital health programs across SMS, mobile applications, WhatsApp, and voice assistants (including Amazon Alexa via the Ring of Support sub-brand), with predictive analytics driving personalization from multi-source inputs including prescription drug claims, wearable device data (Fitbit), ambient mobile/sleep data, EMR data, and behavioral responses. The company's product portfolio is structured as a core platform plus a Creator co-build tool, a Digital Health Marketplace of validated interventions, and a set of sub-branded programs — most notably the A4i (App4Independence) digital therapeutic for schizophrenia and psychosis, operated through a 2016 joint venture (A4i Inc.) with the Centre for Addiction and Mental Health. Other modules include BeWell/Be SaskWell (mental health check-ins, co-created with CAMH and University of Saskatchewan), Resources Around Me (youth mental health resource search engine with Kids Help Phone), Ring of Support (mild cognitive impairment/dementia support with SE Health), SOFIA (SMS intervention for pediatric ADHD adherence), and the recently launched MTxPERT and mtxt.ai generative-AI products.
The company sells primarily to enterprise clients — health systems, mental health centers, pharmaceutical companies, payers, and academic medical centers — under a platform-as-a-service ("MEMOTEXT as a Service" / MaaS) co-creation model, complemented by co-commercialization of pre-validated marketplace solutions. Go-to-market is direct enterprise field sales supported by long-cycle co-development partnerships with named logos including McKesson Canada, SE Health, Novartis Canada, Genentech/Roche, Humana, Green Shield Canada, Boots/Walgreens UK, Johns Hopkins, Vanderbilt, Mass General/Partners Healthcare, SickKids, BC Children's Hospital, and Riverside University Health System. The company holds a patent-pending auditory hallucination detection algorithm and maintains HIPAA, PIPEDA, PHIPA, and GDPR compliance. MEMOTEXT remains a privately-held, founder-led company with 11–50 employees, dual headquarters in Toronto (Canada) and Bethesda, MD (US), and no disclosed institutional funding rounds.
MemoText firmographics
Firmographics- Name
- MemoText
- Legal name
- MEMOTEXT Corporation
- Website
- https://memotext.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MEMOTEXT Corporation is a Toronto-based digital health platform company that co-creates and commercializes personalized, omnichannel patient-engagement programs and digital therapeutics — most notably the A4i schizophrenia DTx via a CAMH joint venture — for enterprise health systems, pharma, payers, and academic medical centers across North America.
- Ownership category
- akta.pro rank
MemoText industry classification
Industry- Product category
- Digital Patient Engagement and Digital Therapeutics Software
- NAICS
- Custom Computer Programming Services (541511), Management Consulting Services (54161)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Programming Services (7371)
- akta.pro primary industry
- Condition-specific Digital Therapeutics (DTx) (HLACANAA)
- akta.pro secondary industries
- DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF), Patient Communications (Reminders/Confirmations/Recalls) (HLACADAH)
Keywords
Where MemoText is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
MemoText business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform as a Service (MaaS): MEMOTEXT as a service enables academics/clinicians and commercial partners to co-create interactive, adaptive, evidence-based engagement communications and digital therapeutics (DTx). They co-commercialize interventions with provider, insurer and pharmaceutical clients on their developing library of digital interventions (digital formulary).
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
MemoText product offering
Product offeringCore offering
MEMOTEXT provides a data-driven, evidence-based personalized digital patient engagement and digital therapeutics (DTx) platform that uses health data (claims, wearables, EMRs, ambient phone data) for risk identification and treatment adherence personalization. The company enables academics, clinicians, and commercial partners to co-create interactive, adaptive, omni-channel engagement communications delivered through SMS, mobile applications, WhatsApp, and voice assistants, and it maintains a marketplace of pre-validated digital interventions for mental health, maternal health, ADHD, hypertension, and dementia.
Product overview
MEMOTEXT is a co-creation digital patient engagement and digital therapeutics platform that operates on a platform-plus-modules architecture. The core MEMOTEXT Platform serves as the foundational technology enabling omnichannel engagement (SMS, mobile app, WhatsApp, voice assistants) powered by predictive analytics and personalization. The platform is extended through the Creator tool (for building custom solutions) and a Marketplace of validated, co-commercialized programs. The product portfolio includes named sub-brands and modules: A4i (a joint-venture digital therapeutic with CAMH for schizophrenia), MTxPERT (AI chatbot assistant), mtxt.ai (AI acceleration layer), Ring of Support (Alexa-powered dementia support platform), BeWell (CAMH/University of Saskatchewan mental health navigator), Resources Around Me (Kids Help Phone youth mental health resource platform), and a COVID-19 assessment solution.
Differentiator
Problem solved
Functional benefit
Brands
- App4Independence (A4i): Validated digital therapeutic mobile app and clinical portal for severe mental illness (schizophrenia, psychosis), featuring auditory hallucination detection, readmission risk prediction, and care coordination tools.
- BeWell
- SOFIA
- Ring of Support
- Resources Around Me
- MTxPERT
Products and services
- MEMOTEXT Platform
- Creator / Creator Components
Quantifiable outcome
- 31.4% medication adherence improvement in randomized control study with Johns Hopkins University
- +4 more outcomes
Companies that use MemoText
Customer profileNamed customers19 records
Segments5 records
Ideal customer profiles4 records
MemoText technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
AI capability10 records
Feature6 records
MemoText partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- STI Technologies (IQVIA Company)corePartnership combining STI's innovative healthcare solutions with MEMOTEXT's personalized engagement technology to enhance patient experience in patient support programs.
- University of New MexicominorCollaboration with Dr. Frank Schwebel at CASAA on digital health tools to support opioid recovery and pain management.
- Waypoint Centre for Mental Health CareminorOBIO-supported partnership to expand A4i Canadian presence across health systems.
- Riverside University Health System - Behavioral HealthcoreSix-month pilot to determine feasibility of deploying A4i in California community mental health clinics at scale. Part of Help@Hand statewide collaborative program.
- CalMHSA Help@HandcoreCalifornia City and County Collaborative to determine if and how technology fits within behavioral health system of care. Partnership to scale A4i across California.
- Centre for Addiction and Mental Health (CAMH)coreJoint venture A4i Inc. created to develop and commercialize award-winning mobile health intervention for schizophrenia. CAMH is Canada's largest mental health teaching hospital. Partnership involves co-development of digital therapeutic platform with clinical and scientific leadership.
- A4i Inc.coreJoint venture company between CAMH and MEMOTEXT to commercialize App4Independence digital therapeutic for schizophrenia and psychosis spectrum illnesses. Led by cross-functional team of digital health, clinical and commercialization experts.
- University of SaskatchewancoreCo-creation of BeWell mental health text-messaging program promoting curated mental health resources and wellness supports. Validated in CIHR-funded study.
- Kids Help PhonecoreCollaboration supporting development and launch of Resources Around Me platform - Canada's largest search engine for youth mental health resources.
- The Royal Ottawa Mental Health CentrecoreOne-year evaluation project with The Royal exploring feasibility of integrating A4i app and clinical portal into clinical practice at Ozerdinc Grimes Family Regional Psychosis Clinic. Funded by OBIO's EAHN.
- SE HealthcoreHome health partnership including care coordination solutions and Ring of Support voice assistant platform for seniors with mild cognitive impairment or early-stage dementia.
- Vanderbilt University Medical Centercore10+ year academic partnership with Dr. Lindsay Mayberry for patient engagement research and validation of digital health solutions.
- Green Shield CanadacoreStick2it program collaboration for medication adherence to cholesterol and hypertension medications with measurable outcomes.
- Ontario Bioscience Innovation Organization (OBIO)coreOBIO Early Adopter Health Network (EAHN) partnership to facilitate technology adoption in Canadian mental healthcare market.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
MemoText competitors and assessment
Company assessmentBroad incumbents
- Headspace Health: Large mental health platform combining consumer content, employer/payer distribution, and digital therapeutic programs (e.g., for depression). Comparable to MEMOTEXT's mental-health DTx portfolio and enterprise health-plan engagement model.
- Propeller Health: Digital therapeutics and connected-device platform for respiratory conditions (now part of ResMed), focused on medication adherence and patient engagement. Comparable in using sensor data and predictive analytics to drive adherence outcomes.
- Omada Health: Larger, venture-backed DTx incumbent focused on diabetes prevention, hypertension, and behavioral health, with payer and employer channels. Comparable to MEMOTEXT's chronic-condition DTx formulary and payer/insurer go-to-market, though at substantially greater scale.
Direct peers
- WellDoc: Chronic care digital therapeutics platform (BlueStar for diabetes) combining patient engagement, predictive analytics, and clinical decision support. Comparable in using multi-source data (claims, devices) for personalized engagement across chronic conditions.
- Akili Interactive: Public DTx company with FDA-cleared prescription digital therapeutics (EndeavorRx for pediatric ADHD) and a broader cognitive DTx pipeline. Directly comparable to MEMOTEXT in building evidence-based, condition-specific DTx for ADHD and mental health via enterprise and pharma channels.
- Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across migraine, schizophrenia, and other indications, with pharma co-commercialization. Closely comparable to MEMOTEXT's evidence-based DTx development model and enterprise pharma positioning.
- Voluntis: Digital therapeutics company (now part of AptarGroup) developing SaMD for chronic conditions including oncology and diabetes, with pharma partnerships. Directly comparable to MEMOTEXT's co-created SaMD model with pharma and provider customers.
- Medisafe: Medication adherence and patient engagement platform with predictive analytics and pharma partnerships. Closely comparable to MEMOTEXT's foundational medication-adherence business and omni-channel engagement approach.
- Big Health: Digital therapeutics company with Sleepio (insomnia) and Daylight (anxiety) products, distributed via payers, providers, and employers. Comparable to MEMOTEXT's mental-health DTx positioning and enterprise health plan channel strategy.
Emerging players
- Happify Health: Digital mental health platform offering prescription and non-prescription digital therapeutics alongside employer/payer distribution. Comparable to MEMOTEXT's mental-health engagement solutions and pharma/payer enterprise motion.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
MemoText social profiles
Digital presenceMemoText compliance and trust
Trust signalCompliance3 records
MemoText financial estimates
Financial estimateRevenue estimate
Valuation estimate
MemoText leadership team
Management profileNumber of profiles
Profiles1 record
MemoText subsidiaries and ownership
Company hierarchySubsidiaries2 records
MemoText funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MemoText M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MemoText
What does MemoText do?
MEMOTEXT provides a data-driven, evidence-based personalized digital patient engagement and digital therapeutics (DTx) platform that uses health data (claims, wearables, EMRs, ambient phone data) for risk identification and treatment adherence personalization. The company enables academics, clinicians, and commercial partners to co-create interactive, adaptive, omni-channel engagement communications delivered through SMS, mobile applications, WhatsApp, and voice assistants, and it maintains a marketplace of pre-validated digital interventions for mental health, maternal health, ADHD, hypertension, and dementia.
Is MemoText a public or private company?
MemoText is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MemoText founded?
MemoText was founded in 2012. It employs 11 to 50 people.
Where is MemoText based?
MemoText is headquartered in Toronto, Canada, in the North America region.
How does MemoText make money?
One revenue line is on record: platform as a Service (MaaS).
Who are MemoText's main competitors?
Broad incumbents on record are Headspace Health, Propeller Health and Omada Health. Direct peers are WellDoc, Akili Interactive, Click Therapeutics, Voluntis, Medisafe and Big Health. Happify Health is listed as an emerging player.
Does MemoText have an API?
No public API is recorded for MemoText.
What industry is MemoText in?
MemoText's product category is Digital Patient Engagement and Digital Therapeutics Software. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 541511 and its SIC code is 7370.